NewTimeSpace News - As of 10:43 on February 5, 2026, Chinese Medicine ETF (159647) gained 0.92%, targeting its third consecutive rise. The latest price reached 0.99 yuan. Looking at a longer timeframe, as of February 4, 2026, the ETF posted a cumulative gain of 0.82% over the past week, ranking 2nd out of 4 comparable funds. (Stocks listed above are constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity, Chinese Medicine ETF recorded an intraday turnover rate of 1.86%, with trading volume reaching 28.6157 million yuan. Looking at a longer timeframe, as of February 4, the average daily trading volume over the past year stood at 33.5263 million yuan.

On the size front, Chinese Medicine ETF's latest assets under management reached 1.524 billion yuan, marking a new high for the past year and ranking 2nd out of 4 comparable funds. (Data source: Wind)

Regarding shares outstanding, Chinese Medicine ETF's latest share count reached 1.553 billion units, marking a new high for the past year and ranking 2nd out of 4 comparable funds. (Data source: Wind)

From a capital flow perspective, Chinese Medicine ETF has seen continuous net capital inflows for the past 8 days, with the highest single-day net inflow reaching 43.3759 million yuan, accumulating to a total of 111 million yuan in attracted funds and an average daily net inflow of 13.8711 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to build positions. Chinese Medicine ETF's latest margin purchase amount reached 2.95 million yuan, with the latest margin financing balance standing at 26.9577 million yuan. (Data source: Wind)

As of February 4, the ETF's NAV has gained 7.89% over the past two years, ranking 1st among comparable funds. In terms of return capability, as of February 4, 2026, since the ETF's inception, its highest monthly return reached 16.26%, with the longest consecutive winning streak lasting 5 months and generating a cumulative gain of 20.28%. The average monthly return during up months stands at 5.20%. As of February 4, 2026, the ETF's annualized excess return over its benchmark over the past two years reached 2.59%, ranking 1st out of 4 comparable funds.

Regarding drawdowns, as of February 4, 2026, the ETF's maximum year-to-date drawdown was 3.91%, with a relative drawdown against its benchmark of 0.03%, the smallest among comparable funds.

On fees, Chinese Medicine ETF's management fee rate is 0.50% and custodian fee rate is 0.10%, the lowest among comparable funds.

In terms of tracking accuracy, as of February 4, 2026, the ETF's tracking error over the past 3 months stood at 0.010%, the highest tracking precision among comparable funds.

From a valuation perspective, the CSI Traditional Chinese Medicine Index tracked by the ETF has a latest price-to-earnings ratio (PE-TTM) of only 24.27x, placing it at the 19.16th percentile over the past year—meaning its valuation is lower than over 80.84% of the time in the past year, positioning it at a historical low.

Chinese Medicine ETF closely tracks the CSI Traditional Chinese Medicine Index, which selects listed securities of companies involved in the production and sales of traditional Chinese medicine as samples to reflect the overall performance of TCM concept listed companies.

Century Securities believes that after experiencing centralized procurement price governance, a series of policies in recent years have continuously focused on registration compliance and inheritance innovation orientation. The TCM industry is expected to welcome a reshuffle. The firm is optimistic about integrated TCM leading enterprises with sufficient reserves of classic famous formulas and evidence-based medicine layout.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.